Cite
MLA Citation
Martin Schuler et al.. “First-line afatinib for advanced EGFRm+ NSCLC: Analysis of long-term responders in the LUX-Lung 3, 6, and 7 trials.” Lung cancer, vol. 133, 2019, pp. 10–19. http://access.bl.uk/ark:/81055/vdc_100085410007.0x000053